158 related articles for article (PubMed ID: 22075465)
21. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
22. [Eribulin in the treatment for metastatic breast cancer].
Manzyuk LV; Kovalenko EI; Artamonova E
Vopr Onkol; 2015; 61(2):195-8. PubMed ID: 26087597
[TBL] [Abstract][Full Text] [Related]
23. Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.
Narayan S; Carlson EM; Cheng H; Condon K; Du H; Eckley S; Hu Y; Jiang Y; Kumar V; Lewis BM; Saxton P; Schuck E; Seletsky BM; Tendyke K; Zhang H; Zheng W; Littlefield BA; Towle MJ; Yu MJ
Bioorg Med Chem Lett; 2011 Mar; 21(6):1634-8. PubMed ID: 21324692
[TBL] [Abstract][Full Text] [Related]
24. Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer.
Prestifilippo A; Grippaldi D; Blanco G; Memeo L; Puliafito I; Giuffrida D
Future Oncol; 2017 Apr; 13(11s):5-10. PubMed ID: 28481186
[TBL] [Abstract][Full Text] [Related]
25. Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
Towle MJ; Nomoto K; Asano M; Kishi Y; Yu MJ; Littlefield BA
Anticancer Res; 2012 May; 32(5):1611-9. PubMed ID: 22593439
[TBL] [Abstract][Full Text] [Related]
26. Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.
Rau KM; Ou-Yang F; Chao TC; Kuo YL; Cheng TF; Chao TY; Chen DR; Tzeng YD; Wang BW; Liu CY; Hu MH; Lu YC; Ou WJ; Kuo CH; Chuang CH; Kan JY; Chen FM; Hou MF
Breast Cancer Res Treat; 2018 Aug; 170(3):583-591. PubMed ID: 29623575
[TBL] [Abstract][Full Text] [Related]
27. Eribulin mesylate.
Huyck TK; Gradishar W; Manuguid F; Kirkpatrick P
Nat Rev Drug Discov; 2011 Mar; 10(3):173-4. PubMed ID: 21358731
[No Abstract] [Full Text] [Related]
28. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
Scarpace SL
Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
[TBL] [Abstract][Full Text] [Related]
29. Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).
Ohtani S; Nakayama T; Yoshinami T; Watanabe KI; Hara F; Sagara Y; Kawaguchi H; Higaki K; Matsunami N; Hasegawa Y; Takahashi M; Mizutani M; Morimoto T; Sato M; Itoh M; Morita S; Masuda N
Breast Cancer; 2018 Jul; 25(4):438-446. PubMed ID: 29435730
[TBL] [Abstract][Full Text] [Related]
30. Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.
Reda M; Macaire P; Bellio H; Uwer L; Ilie S; Lorgis V; Hennequin A; Ladoire S; Rederstorff E; Fumoleau P; Isambert N; Bonnin N; You B; Freyer G; Desmoulins I; Schmitt A
Cancer Chemother Pharmacol; 2022 Feb; 89(2):197-208. PubMed ID: 34997290
[TBL] [Abstract][Full Text] [Related]
31. Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
Aseyev O; Ribeiro JM; Cardoso F
Expert Opin Pharmacother; 2016; 17(4):589-600. PubMed ID: 26809667
[TBL] [Abstract][Full Text] [Related]
32. Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPiO study.
Barni S; Livraghi L; Gravina A; Martella F; D'Onofrio L; Morritti M; Michelotti A; Vici P; Mentuccia L; Porcu L; Orditura M; Puglisi F;
J Geriatr Oncol; 2019 Nov; 10(6):990-993. PubMed ID: 31097340
[No Abstract] [Full Text] [Related]
33. Retrospective analysis of the efficacy and safety of eribulin therapy for metastatic breast cancer in daily practice.
Tanaka T; Ueno M; Nakashima Y; Chinen S; Sato E; Masaki M; Mogi A; Sasaki H; Tamura K; Takamatsu Y
Thorac Cancer; 2017 Sep; 8(5):523-529. PubMed ID: 28741868
[TBL] [Abstract][Full Text] [Related]
34. Ixabepilone (Ixempra) for breast cancer.
Med Lett Drugs Ther; 2008 Jan; 50(1278):7-8. PubMed ID: 18219261
[No Abstract] [Full Text] [Related]
35. Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer.
Cortes J; Lorca R
Future Oncol; 2011 Mar; 7(3):355-64. PubMed ID: 21375468
[TBL] [Abstract][Full Text] [Related]
36. Effects of eribulin on microtubule binding and dynamic instability are strengthened in the absence of the βIII tubulin isotype.
Wilson L; Lopus M; Miller HP; Azarenko O; Riffle S; Smith JA; Jordan MA
Biochemistry; 2015 Oct; 54(42):6482-9. PubMed ID: 26435331
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function.
Tan AR; Sarantopoulos J; Lee L; Reyderman L; He Y; Olivo M; Goel S
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1051-61. PubMed ID: 26433580
[TBL] [Abstract][Full Text] [Related]
38. Approved agents for metastatic breast cancer.
Fornier MN
Semin Oncol; 2011 Jun; 38 Suppl 2():S3-10. PubMed ID: 21600382
[TBL] [Abstract][Full Text] [Related]
39. Eribulin as an effective monotherapy in a chemo-pretreated woman with metastatic breast cancer: a case report.
Caputo R; Cianniello D; De Laurentiis M
Future Oncol; 2017 Apr; 13(11s):45-50. PubMed ID: 28481184
[TBL] [Abstract][Full Text] [Related]
40. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
Park YH; Kim TY; Im YH; Lee KS; Park IH; Sohn J; Lee SH; Im SA; Kim JH; Kim SH; Lee SJ; Koh SJ; Lee KH; Choi YJ; Cho EK; Lee S; Kang SY; Seo JH; Kim SB; Jung KH
Cancer Res Treat; 2017 Apr; 49(2):423-429. PubMed ID: 27488876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
